Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia

13 Mar 2010

Abstract excerpt

A consistently increased mRNA expression of the adhesion receptor CD11b is a hallmark of the reported genomewide gene expression changes in precursor B-cell acute lymphoblastic leukemia (PBC-ALL) after 1 week of induction therapy. To investigate its clinical relevance, CD11b protein expression in leukemic blasts has been prospectively measured at diagnosis (159 patients) and during therapy (53 patients). The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20228269
DOI: 10.1182/blood-2009-10-247585

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemiaPMID 20228269Read ↗

Immunophenotypic portrait of leukemia‐associated‐phenotype markers in B acute lymphoblastic leukemiaSemantic proximity Read ↗

The T-ALL related gene BCL11B regulates the initial stages of human T-cell differentiationSemantic proximity Read ↗

Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemiaSemantic proximity Read ↗

A comprehensive assessment of the prognostic role of cell adhesion molecules in acute myeloid leukemiaSemantic proximity Read ↗

Extracellular matrix protein 1 (ECM1) is a potential biomarker in B-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

CD304 is preferentially expressed on a subset of B‐lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometrySemantic proximity Read ↗

Structural analysis of the CD11b gene and phylogenetic analysis of the alpha-integrin gene family demonstrate remarkable conservation of genomic organization and suggest early diversification during evolution.Semantic proximity Read ↗

Adhesion molecule expression on B-cells from acute and chronic lymphoid leukemias.Semantic proximity Read ↗

Cadherins, Selectins, and Integrins in CAM-DR in LeukemiaSemantic proximity Read ↗

High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapseSemantic proximity Read ↗

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaSemantic proximity Read ↗

Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.